Clinical Trial Update: Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging safety and tolerability study in adults aged 60 and older with Alzheimer's disease has been completed; results were posted in May 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-05-25